SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Celldex Therapeutics, Inc. (CLDX) has a negative trailing P/E of -8.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 8.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -11.70%, forward earnings yield 12.45%.
Criteria proven by this page:
- VALUE (33/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -8.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -11.70%); analyst consensus target implies downside from the current price ($24.00, 28%).
- Forward P/E 8.0 — analysts expect a return to profitability with estimated EPS of $4.15 for FY2030.
- Trailing Earnings Yield -11.70% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 12.45% as earnings recover.
- Analyst consensus target $24.00 (-28% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 45/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
33/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CLDX
Valuation Multiples
P/E (TTM)-8.5
Forward P/E8.0
PEG RatioN/A
Forward PEGN/A
P/B Ratio4.20
P/S Ratio1,476.53
EV/EBITDA-7.9
Per Share Data
EPS (TTM)$-3.89
Forward EPS (Est.)$4.15
Book Value / Share$7.93
Revenue / Share$0.02
FCF / Share$-3.21
Yields & Fair Value
Earnings Yield-11.70%
Forward Earnings Yield12.45%
Dividend Yield0.00%
Analyst Target$24.00 (-28%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-2.8 |
0.82 |
1.35 |
52.96 |
- |
| 2017 |
-3.9 |
0.09 |
1.54 |
28.65 |
- |
| 2018 |
-0.2 |
-0.01 |
0.25 |
3.28 |
- |
| 2019 |
-0.6 |
0.01 |
0.34 |
9.05 |
- |
| 2020 |
-8.7 |
0.20 |
2.48 |
70.00 |
- |
| 2021 |
-23.5 |
1.25 |
3.95 |
356.16 |
- |
| 2022 |
-18.6 |
-0.40 |
6.41 |
886.63 |
- |
| 2023 |
-13.6 |
-0.63 |
4.48 |
279.16 |
- |
| 2024 |
-10.3 |
0.64 |
2.18 |
231.80 |
- |
| 2025 |
-7.0 |
-0.12 |
3.43 |
1,204.09 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-18.99 |
$6.79M |
$-128.53M |
-1894% |
| 2017 |
$-10.86 |
$12.74M |
$-93.03M |
-730.1% |
| 2018 |
$-14.48 |
$9.54M |
$-151.18M |
-1585.1% |
| 2019 |
$-3.47 |
$3.57M |
$-50.37M |
-1409.8% |
| 2020 |
$-2.02 |
$7.42M |
$-59.78M |
-805.9% |
| 2021 |
$-1.64 |
$4.65M |
$-70.51M |
-1516% |
| 2022 |
$-2.62 |
$2.36M |
$-122.78M |
-5209.3% |
| 2023 |
$-2.92 |
$6.88M |
$-141.43M |
-2054.8% |
| 2024 |
$-2.45 |
$7.02M |
$-157.86M |
-2248.8% |
| 2025 |
$-3.90 |
$1.5M |
$-258.8M |
-17253.3% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-4.83 |
$-5.15 – $-4.25 |
$2.63M |
$666.33K – $5.71M |
10 |
| 2027 |
$-4.82 |
$-5.13 – $-4.42 |
$12.29M |
$1.33M – $33.26M |
8 |
| 2028 |
$-3.63 |
$-5.17 – $-1.55 |
$126.54M |
$120.86M – $132.23M |
9 |
| 2029 |
$-0.16 |
$-0.47 – $0.02 |
$471.29M |
$71.6M – $1.2B |
3 |
| 2030 |
$4.15 |
$-0.43 – $12.49 |
$890.91M |
$135.35M – $2.27B |
3 |
